



15 October 2024

Argent BioPharma Ltd.
(Argent BioPharma or the Company)

Notice Under Section 708A(5) of the Corporations Act 2001 (the Act)

This notice is given by Argent BioPharma Limited (ASX: RGT) (**Argent BioPharma** or the **Company**) in relation to the issue of 4,200,000 fully paid ordinary shares (**Shares**) as detailed in the Appendix 2A's announced today.

The Corporations Act 2001 (Cth) (**Act**) restricts the on-sale of securities issued without disclosure unless the sale is exempt under section 708 or 708A of the Act. By giving this notice, the Shares detailed in the Appendix 2A's announced on 15 October 2024 will fall within the exemption in section 708A(5) of the Act. Pursuant to section 708A(5)(e) of the Act, the Company gives notice that:

- a) the Company issued the Shares without disclosure to investors under Part 6D.2 of the Act;
- b) as at the date of this notice the Company has complied with the provisions of Chapter 2M of the Act as they apply to the Company, and sections 674 and 674A of the Act; and
- c) as at the date of this notice there is no information:
 - 1) that has been excluded from a continuous disclosure notice in accordance with the Listing Rules; and
 - 2) that investors and their professional advisors would reasonably require for the purpose of making an informed assessment of:
 - i. the assets and liabilities, financial position and performance, profits and losses and prospects of the Company; or
 - ii. the rights and liabilities attaching to the Shares.

—Ends—

Authorised for release by the board of directors, for further information please contact:

Argent BioPharma
Roby Zomer
CEO & Managing Director
+61 8 6555 2950
info@argentbiopharma.com

Argent BioPharma
Rowan Harland
Company Secretary
+61 8 6555 2950
info@argentbiopharma.com



About Argent BioPharma

Argent BioPharma Limited (the “**Company**”) (ASX: RGT; LSE: RGT; OTCQB: RGTLF) an innovative multidisciplinary drug development Company within the biopharmaceutical sector. The Company focuses on multidisciplinary methods with Nanotechnology, developing multi-target therapies for comprehensive disease management, especially concerning the Central nervous system (“CNS”) and Immunology treatments.

Follow us through our social media channels:

LinkedIn: Argent BioPharma

Twitter: @ArgentBioPharma

Facebook: Argent BioPharma